Document is current

Article History

Accepted: 7 October 2020

First Online: 18 October 2020

Declarations

:

: This work was supported by Takeda Pharmaceutical Company Limited, manufacturer/licensee of vortioxetine in the USA and in Japan in alliance with Lundbeck AS. Takeda was involved in the study design, data collection, data analysis, and preparation of the manuscript.

: Tatsuo Akechi has received lecture fees from Astellas, AstraZeneca, Daiichi-Sankyo, Dainippon-Sumitomo, Eisai, Hisamitsu, Kyowa-hakko Kirin, Kyowa, Eli Lilly, MSD, Meiji-seika Pharma, Mochida, Mundipharma, Otsuka, Pfizer, Shionogi, Terumo, and Tsumura, and has received research funds from Daiichi-Sankyo, Eisai, FUJIFILM RI Pharma, Eli Lilly, MSD, Novartis, Otsuka, Shionogi, and Tanabe-Mitsubishi. Izumi Mishiro, Shinji Fujimoto, and Katsuhito Murase are employees of Takeda Pharmaceutical Company Limited.

: This study used anonymized information from the JMDC database; therefore, in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan, institutional ethics approval was not required.

: This study used anonymized information from the JMDC database; therefore, in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan, informed consent was not required.

: Not applicable.

: The data that support the findings of this study are available from JMDC Inc. but were used under license for the current study; therefore, restrictions apply and the data are not publicly available. For inquiries about access to the data set used in this study, please contact JMDC (ExternalRef removed).

: Not applicable.

: All authors were investigators in the study and participated in the study design, interpretation of the study results, and in the drafting, critical revision, and approval of the final version of the manuscript. IM conducted the statistical analysis.